Press Releases

Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe
Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel
Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018
Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
Arch Therapeutics Provides Skin Sensitization Study Status Update
RSS
Show All